Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 26Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Melanoma 11Lung Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasms 5Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Uncommon Pathological Types of Lung Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Sexual Dysfunction, Physiological 1Sarcopenia 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1NSCLC 1Motor Activity 1Lung Squamous Cell Carcinoma Stage IV 1Lung Diseases, Interstitial 1Liver Diseases 1Kidney Neoplasms 1

Interventions

Gene Expression Profiling 9Blood Specimen Collection 6Polymerase Chain Reaction 5Immunohistochemistry 5Amplified Fragment Length Polymorphism Analysis 5Surveys and Questionnaires 3Sunitinib 3Reverse Transcriptase Polymerase Chain Reaction 3Flow Cytometry 3Biopsy 3Surgical Procedures, Operative 2Radiotherapy 2Radiosurgery 2Patient Reported Outcome Measures 2Observation 2Nivolumab 2Microarray Analysis 2Immunotherapy 2Genetic Testing 2Drug Therapy 2DNA Methylation 2Cytogenetic Analysis 2tremelimumab 1pembrolizumab 1durvalumab 1atezolizumab 1aldesleukin 1X-Rays 1Watchful Waiting 1Tomography, Optical Coherence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Kidney Neoplasms × pembrolizumab × Clear all
NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Cambridge University Hospitals NHS Foundation Trust

Unknown
1,800 enrolled
DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡